相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
Emma C. Morris et al.
NATURE REVIEWS IMMUNOLOGY (2022)
Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma
Yoshitaka Narita et al.
NEURO-ONCOLOGY (2021)
The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma
Xiuli Wang et al.
CANCER IMMUNOLOGY RESEARCH (2021)
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Paul Baas et al.
LANCET (2021)
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET ONCOLOGY (2021)
Microglia and Central Nervous System-Associated Macrophages-From Origin to Disease Modulation
Marco Prinz et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 39 (2021)
A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity
Morgane Boulch et al.
SCIENCE IMMUNOLOGY (2021)
Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma
Cedric Menard et al.
BLOOD ADVANCES (2021)
MATRIX INDUCTION FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT OR WHOLE‐BRAIN IRRADIATION IN PRIMARY CNS LYMPHOMA. 7‐YEAR RESULTS OF THE IELSG32 RANDOMIZED TRIAL
J. A. Mutter et al.
HEMATOLOGICAL ONCOLOGY (2021)
Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma
Andrea Cugurra et al.
SCIENCE (2021)
Heterogeneity of meningeal B cells reveals a lymphopoietic niche at the CNS borders
Simone Brioschi et al.
SCIENCE (2021)
CAR T-Cells for CNS Lymphoma: Driving into New Terrain?
Philipp Karschnia et al.
CANCERS (2021)
The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling
Melissa Alame et al.
THERANOSTICS (2021)
Allogeneic hematopoietic stem cell transplantation for primary central nervous system lymphoma
Thomas Mika et al.
HAEMATOLOGICA (2020)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
Jordan Gauthier et al.
BLOOD (2020)
Management and outcome of primary CNS lymphoma in the modern era An LOC network study
Caroline Houillier et al.
NEUROLOGY (2020)
Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas
Melissa Alame et al.
VIRCHOWS ARCHIV (2020)
In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy
Lukas Marcelis et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain
Tongjuan Li et al.
FRONTIERS IN ONCOLOGY (2020)
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
Chelsea C. Pinnix et al.
BLOOD ADVANCES (2020)
Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies
Kevin R. Parker et al.
CELL (2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf et al.
LANCET (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Nivolumab in Primary CNS Lymphoma and Primary Testicular Lymphoma with CNS Involvement: Single Center Experience
Andrey N. Gavrilenko et al.
BLOOD (2020)
First Results of the Acse Pembrolizumab Phase II in the Primary CNS Lymphoma (PCNSL) Cohort
Khe Hoang-Xuan et al.
BLOOD (2020)
Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)
Sattva S. Neelapu et al.
BLOOD (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)
H. Ghesquieres et al.
ANNALS OF ONCOLOGY (2019)
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results o the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study
Caroline Houillier et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma
Matthew J. Frigault et al.
BLOOD (2019)
Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma
Austin J. Sim et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
Robert Chen et al.
BLOOD (2019)
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network
C. Soussain et al.
EUROPEAN JOURNAL OF CANCER (2019)
Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis
Andreas M. Schmitt et al.
HEMATOLOGICAL ONCOLOGY (2019)
Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice
Matthias Mulazzani et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study
Jacoline E. C. Bromberg et al.
LANCET ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Naive T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers
Rajat K. Das et al.
CANCER DISCOVERY (2019)
Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia
Helen M. Parry et al.
FRONTIERS IN IMMUNOLOGY (2019)
Ibrutinib brain distribution: a preclinical study
Lauriane Goldwirt et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
Margaretha G. M. Roemer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma
Han W. Tun et al.
BLOOD (2018)
Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia
Georg Aue et al.
JOURNAL OF IMMUNOLOGY (2018)
Direct vascular channels connect skull bone marrow and the brain surface enabling myeloid cell migration
Fanny Herisson et al.
NATURE NEUROSCIENCE (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma
James L. Rubenstein et al.
BLOOD ADVANCES (2018)
The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma
Yuko Miyasato et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY (2018)
Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma
Xiuli Wang et al.
CLINICAL CANCER RESEARCH (2018)
Ibrutinib treatment improves T cell number and function in CLL patients
Meixiao Long et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma
Hyunsoo Cho et al.
ONCOTARGET (2017)
Human and nonhuman primate meninges harbor lymphatic vessels that can be visualized noninvasively by MRI
Martina Absinta et al.
ELIFE (2017)
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial
Andres J. M. Ferreri et al.
LANCET HAEMATOLOGY (2017)
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Michail S. Lionakis et al.
CANCER CELL (2017)
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma
Lakshmi Nayak et al.
BLOOD (2017)
Targetable genetic features of primary testicular and primary central nervous system lymphomas
Bjoern Chapuy et al.
BLOOD (2016)
Tumor-Associated Macrophages Associate with Cerebrospinal Fluid Interleukin-10 and Survival in Primary Central Nervous System Lymphoma (PCNSL)
Takashi Sasayama et al.
BRAIN PATHOLOGY (2016)
A network map of Interleukin-10 signaling pathway
Renu Verma et al.
JOURNAL OF CELL COMMUNICATION AND SIGNALING (2016)
Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment
Andrew Stiff et al.
CANCER RESEARCH (2016)
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
Marco Ruella et al.
CLINICAL CANCER RESEARCH (2016)
The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients
Ludovic Nguyen-Them et al.
EUROPEAN JOURNAL OF CANCER (2016)
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Margaretha G. M. Roemer et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network
Sophie Langner-Lemercier et al.
NEURO-ONCOLOGY (2016)
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
Andres J. M. Ferreri et al.
LANCET HAEMATOLOGY (2016)
Cerebrospinal Fluid IL-10 and IL-10/IL-6 as Accurate Diagnostic Biomarkers for Primary Central Nervous System Large B-cell Lymphoma
Yang Song et al.
SCIENTIFIC REPORTS (2016)
Preclinical Evaluation of Ibrutinib for Central Nervous System Lymphoma
Frederic Pouzoulet et al.
BLOOD (2016)
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
H. Tilly et al.
ANNALS OF ONCOLOGY (2015)
Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds
Kathryn Lagrue et al.
BLOOD (2015)
Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses
S. Kuramitsu et al.
CANCER GENE THERAPY (2015)
A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules
Aleksanteri Aspelund et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Structural and functional features of central nervous system lymphatic vessels
Antoine Louveau et al.
NATURE (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Complement Activation and Intraventricular Rituximab Distribution in Recurrent Central Nervous System Lymphoma
Cigall Kadoch et al.
CLINICAL CANCER RESEARCH (2014)
High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma
Matthias Holdhoff et al.
NEUROLOGY (2014)
Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma
James L. Rubenstein et al.
BLOOD (2013)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Lenalidomide enhances anti-myeloma cellular immunity
Katarina Luptakova et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Pomalidomide Shows Significant Therapeutic Activity against CNS Lymphoma with a Major Impact on the Tumor Microenvironment in Murine Models
Zhimin Li et al.
PLOS ONE (2013)
Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases
Carole Soussain et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Rituximab significantly improves complete response rate in patients with primary CNS lymphoma
Tobias Birnbaum et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid β
Jeffrey J. Iliff et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Age, gender, and racial differences in incidence and survival in primary CNS lymphoma
J. L. Villano et al.
BRITISH JOURNAL OF CANCER (2011)
RITUXIMAB MONOTHERAPY FOR PATIENTS WITH RECURRENT PRIMARY CNS LYMPHOMA
T. T. Batchelor et al.
NEUROLOGY (2011)
Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells
Daniel Venetz et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma
Kristoph Jahnke et al.
NEURO-ONCOLOGY (2009)
Pathway analysis of primary central nervous system lymphoma
Han W. Tun et al.
BLOOD (2008)
Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment
James Rubenstein et al.
LEUKEMIA & LYMPHOMA (2008)
Expression pattern and cellular sources of chemokines in primary central nervous system lymphoma
Anna Brunn et al.
ACTA NEUROPATHOLOGICA (2007)
Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas
M. Ponzoni et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Chemotherapy delivery issues in central nervous system malignancy: A reality check
Leslie L. Muldoon et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma
James L. Rubenstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gene expression and angiotropism in primary CNS lymphoma
JL Rubenstein et al.
BLOOD (2006)
A uniform activated B-cell-like in-immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases
S Camilleri-Broet et al.
BLOOD (2006)
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma
LE Abrey et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Targeting tumours with genetically enhanced T lymphocytes
M Sadelain et al.
NATURE REVIEWS CANCER (2003)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
分享论文
